Organic Sales Growth
QuidelOrtho reported an organic sales growth of 5%, excluding COVID sales and the U.S. donor screening business exit, demonstrating the strength of their diversified global diagnostics portfolio.
Improved Adjusted EBITDA
Adjusted EBITDA expanded to 25% of sales, driven by margin improvement initiatives that delivered over $140 million in cost savings.
Strong Regional Performance
Excluding COVID, Latin America led with 21% overall growth, and 22% in labs. Japan, Asia Pacific, and China each grew approximately 5%, and Europe, Middle East, and Africa grew 3%.
High-Sensitivity Troponin Assay
FDA clearance for VITROS high-sensitivity troponin assay was achieved in 90 days, enhancing the cardiac panel's competitiveness.
Cost Savings Achievements
The company achieved significant cost savings, with adjusted EBITDA margin improving by 180 basis points from the prior year.